IR@PKUHSC  > 北京大学第二临床医学院  > 血液科
学科主题临床医学
Low-dose methotrexate for the treatment of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation
Huang, XJ; Jiang, Q; Chen, H; Xu, L; Liu, D; Chen, Y; Han, W; Zhang, Y; Liu, K; Lu, D
关键词hematopoietic stem cell transplantation allogeneic methotrexate graft-versus-host disease
刊名BONE MARROW TRANSPLANTATION
2005-08-01
DOI10.1038/sj.bmt.1705034
36期:4页:343-348
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Biophysics ; Oncology ; Hematology ; Immunology ; Transplantation
研究领域[WOS]Biophysics ; Oncology ; Hematology ; Immunology ; Transplantation
关键词[WOS]BONE-MARROW-TRANSPLANTATION ; SALVAGE THERAPY ; CYCLOSPORINE ; PREDNISONE ; MODERATE
英文摘要

Methotrexate (MTX) is commonly used in the prophylaxis of graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (alloHSCT). In order to evaluate the efficacy and safety of low-dose MTX treatment in patients with GVHD after allo-HSCT, 38 patients with acute GVHD (aGVHD), chronic GVHD (cGVHD) or GVHD post-donor lymphocyte infusion (post-DLI GVHD) after allo-HSCT received intravenous MTX at a dose of 5 or 10mg every 5-7 days until a complete or partial response was seen, or there was treatment failure or intolerable side effects. The overall response rate was 94.7% (18/19 patients) in patients with aGVHD, 76.2% (16/21 patients) in patients with cGVHD and 2/2 in patients with post-DLI GVHD. The response rate for GVHD involving various organs was 100% in skin, 75% in gut, 55.6% in liver, 75% in mouth and 100% in the eye, among all enrolled patients. Side effects were minor. Short-term, low-dose MTX is a tolerable and an effective regimen for patients with aGVHD, cGVHD or post-DLI GVHD after allo-HSCT.

语种英语
WOS记录号WOS:000230895400010
引用统计
被引频次:37[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/60995
专题北京大学第二临床医学院_血液科
作者单位Peking Univ, Inst Hematol, People Hosp, Beijing 100044, Peoples R China
推荐引用方式
GB/T 7714
Huang, XJ,Jiang, Q,Chen, H,et al. Low-dose methotrexate for the treatment of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation[J]. BONE MARROW TRANSPLANTATION,2005,36(4):343-348.
APA Huang, XJ.,Jiang, Q.,Chen, H.,Xu, L.,Liu, D.,...&Lu, D.(2005).Low-dose methotrexate for the treatment of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.BONE MARROW TRANSPLANTATION,36(4),343-348.
MLA Huang, XJ,et al."Low-dose methotrexate for the treatment of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation".BONE MARROW TRANSPLANTATION 36.4(2005):343-348.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Huang, XJ]的文章
[Jiang, Q]的文章
[Chen, H]的文章
百度学术
百度学术中相似的文章
[Huang, XJ]的文章
[Jiang, Q]的文章
[Chen, H]的文章
必应学术
必应学术中相似的文章
[Huang, XJ]的文章
[Jiang, Q]的文章
[Chen, H]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。